PRESERT: linking prefrontal cortex, serotonin transporter and social cognition.
Neuropsychiatric and neurodevelopmental disorders are a heterogeneous group of mental diseases affecting about 1 billion people worldwide. Common alterations are in the cognitive and social domains, having a critical impact on the...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
SEROTONIN and BEYOND
Serotonin and BEYOND Brain development research Excelling Y...
4M€
Cerrado
SEROTONIN IN ACTION
Serotonergic modulation of cortical activity in vivo from n...
222K€
Cerrado
SAF2012-35183
PAPEL DE LA CORTEZA INFRALIMBICA EN DEPRESION: CONECTIVIDAD...
351K€
Cerrado
RAPHE
Cell type specific features of serotonergic neurons in the r...
156K€
Cerrado
PID2019-104683RB-I00
SUSTRATOS NEURALES DE LA ACCION PROCOGNITIVA MEDIADA POR REC...
155K€
Cerrado
TWO-BIRDS
A feasibility study for SYT 510 a first in class drug to tr...
71K€
Cerrado
Información proyecto PRESERT
Duración del proyecto: 35 meses
Fecha Inicio: 2024-04-19
Fecha Fin: 2027-03-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Neuropsychiatric and neurodevelopmental disorders are a heterogeneous group of mental diseases affecting about 1 billion people worldwide. Common alterations are in the cognitive and social domains, having a critical impact on the public health, daily life, and long-term outcomes of affected patients. Unfortunately, efficient pharmacological interventions are still missing. The serotonin transporter (SERT) re-uptakes serotonin after synaptic release and is an important clinical target. SERT is widely expressed in the prefrontal cortex (PFC), an area profoundly engaged in socio-cognitive functions, and can be targeted by inhibitors -drugs acting by blocking the transporter- or by releasers- drugs acting as a substrate of SERT and then reversing its transport direction. The SERT releaser MDMA showed promising results for treating social dysfunctions in post-traumatic stress disorder and autism spectrum disorders and its pro-social effect seems dependent on SERT-reverse transport. Considering the efficacy of the SERT-releaser MDMA in modulating social dysfunctions, together with the need of SERT-reverse functions in mediating MDMA pro-social effects, and the role of the PFC in the regulation of socio-cognitive functions, the aim of PRESERT is to evaluate the impact of SERT on social cognition in mice. To achieve this overarching goal, PRESERT is divided into three specific objectives: i) investigating the impact of the PFC-expressed SERT on social cognition, ii) identifying the origin and connectivity of the underlying SERT-expressing circuits, and iii) evaluating if social cognition can be differentially modulated by the reverse transport (i.e. efflux) or the simple inhibition of SERT. As a direct consequence, PRESERT has the potential to link SERT, its molecular functions, and the underlying brain circuits to specific aspects of social cognition setting the ground for the development of innovative treatments for neuropsychiatric disorders.